Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02736123
Title Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Pittsburgh
Indications

melanoma

Therapies

Nivolumab

Ipilimumab + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.